Clinical Trial

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine if EL219 is safe and effective compared to liposomal amphotericin B (LAmB) or voricanozole for early treatment of invasive mould infections
Protocol Amendment History 6 changes
notable Trial sites expanded: 15 -> 18 locations 2026-07-09
notable Trial sites expanded: 12 -> 15 locations 2026-06-26
notable Enrollment reduced: 80 -> 60 participants 2026-05-07
notable Trial sites expanded: 2 -> 6 locations 2026-05-07
notable Primary completion pushed: 2026-11 -> 2026-12 2026-05-07
minor Completion pushed: 2026-11 -> 2026-12 2026-05-07
Trial Details
NCT Number NCT07215273
Lead Sponsor Elion Therapeutics, Inc.
Conditions Invasive Mould Infection
Enrollment 60 participants
Start Date 2026-02-13
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-05